| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Carcinoma, Non-Small-Cell Lung | 26 | 2020 | 300 | 6.490 |
Why?
|
| Lung Neoplasms | 32 | 2020 | 1173 | 5.310 |
Why?
|
| Esophageal Neoplasms | 10 | 2020 | 150 | 2.880 |
Why?
|
| Lung Transplantation | 7 | 2021 | 88 | 2.660 |
Why?
|
| Reperfusion Injury | 4 | 2018 | 320 | 1.810 |
Why?
|
| Lung Injury | 3 | 2018 | 38 | 1.600 |
Why?
|
| Pneumonectomy | 10 | 2019 | 79 | 1.590 |
Why?
|
| Adenocarcinoma | 7 | 2017 | 475 | 1.430 |
Why?
|
| Neoplasm Staging | 15 | 2020 | 800 | 1.380 |
Why?
|
| Lung | 6 | 2019 | 849 | 1.290 |
Why?
|
| Humans | 80 | 2021 | 68618 | 1.060 |
Why?
|
| Carcinoma, Squamous Cell | 4 | 2017 | 629 | 1.000 |
Why?
|
| Thoracic Surgery, Video-Assisted | 5 | 2017 | 19 | 0.970 |
Why?
|
| Lung Diseases | 3 | 2019 | 175 | 0.960 |
Why?
|
| Radiosurgery | 3 | 2020 | 66 | 0.880 |
Why?
|
| Anastomotic Leak | 2 | 2020 | 11 | 0.830 |
Why?
|
| Protein Kinase Inhibitors | 3 | 2020 | 331 | 0.830 |
Why?
|
| Endosonography | 2 | 2012 | 177 | 0.770 |
Why?
|
| Opiate Alkaloids | 1 | 2020 | 6 | 0.750 |
Why?
|
| Neoplasms, Germ Cell and Embryonal | 1 | 2020 | 15 | 0.750 |
Why?
|
| Testicular Neoplasms | 1 | 2020 | 27 | 0.740 |
Why?
|
| Thymus Neoplasms | 1 | 2020 | 17 | 0.730 |
Why?
|
| Thoracic Surgery | 2 | 2018 | 72 | 0.720 |
Why?
|
| Acrylamides | 1 | 2020 | 12 | 0.720 |
Why?
|
| Neuropilin-2 | 1 | 2020 | 19 | 0.720 |
Why?
|
| Social Behavior | 1 | 2021 | 164 | 0.710 |
Why?
|
| Neoplasms, Glandular and Epithelial | 1 | 2020 | 22 | 0.710 |
Why?
|
| Aniline Compounds | 1 | 2020 | 52 | 0.710 |
Why?
|
| Neoadjuvant Therapy | 3 | 2020 | 104 | 0.710 |
Why?
|
| Pulmonary Artery | 2 | 2015 | 323 | 0.700 |
Why?
|
| Surgeons | 1 | 2020 | 68 | 0.690 |
Why?
|
| Trachea | 2 | 2010 | 48 | 0.670 |
Why?
|
| Bone and Bones | 1 | 2020 | 145 | 0.660 |
Why?
|
| Bronchoscopy | 3 | 2019 | 147 | 0.660 |
Why?
|
| Pharmaceutical Preparations | 1 | 2020 | 101 | 0.650 |
Why?
|
| Antineoplastic Agents | 6 | 2020 | 1070 | 0.650 |
Why?
|
| Thoracic Duct | 2 | 2018 | 6 | 0.650 |
Why?
|
| Publishing | 1 | 2020 | 89 | 0.640 |
Why?
|
| Drug Resistance, Neoplasm | 2 | 2020 | 332 | 0.630 |
Why?
|
| Lymphography | 1 | 2018 | 3 | 0.630 |
Why?
|
| Apoptosis | 10 | 2008 | 1641 | 0.620 |
Why?
|
| Matrix Metalloproteinase 12 | 1 | 2018 | 31 | 0.610 |
Why?
|
| Mentoring | 1 | 2018 | 53 | 0.600 |
Why?
|
| Multiple Pulmonary Nodules | 1 | 2018 | 41 | 0.590 |
Why?
|
| Living Donors | 1 | 2019 | 160 | 0.590 |
Why?
|
| Lymph Nodes | 3 | 2017 | 258 | 0.530 |
Why?
|
| Esophagectomy | 6 | 2017 | 26 | 0.530 |
Why?
|
| Myocardial Reperfusion Injury | 1 | 2016 | 84 | 0.530 |
Why?
|
| Male | 33 | 2021 | 37321 | 0.520 |
Why?
|
| Aortic Aneurysm, Thoracic | 1 | 2017 | 134 | 0.510 |
Why?
|
| Pulmonary Circulation | 1 | 2015 | 79 | 0.500 |
Why?
|
| Phenylbutyrates | 1 | 2014 | 7 | 0.500 |
Why?
|
| Arterial Pressure | 1 | 2015 | 47 | 0.500 |
Why?
|
| Bronchiolitis Obliterans | 1 | 2014 | 15 | 0.500 |
Why?
|
| Toll-Like Receptor 2 | 1 | 2015 | 34 | 0.490 |
Why?
|
| Azithromycin | 1 | 2014 | 13 | 0.490 |
Why?
|
| Hepatocyte Growth Factor | 1 | 2015 | 63 | 0.490 |
Why?
|
| Gene Knockdown Techniques | 1 | 2015 | 196 | 0.490 |
Why?
|
| Chemokine CCL2 | 1 | 2015 | 101 | 0.490 |
Why?
|
| Thoracic Surgical Procedures | 2 | 2017 | 37 | 0.490 |
Why?
|
| Tissue and Organ Procurement | 1 | 2017 | 164 | 0.490 |
Why?
|
| Matrix Metalloproteinase Inhibitors | 1 | 2014 | 59 | 0.480 |
Why?
|
| RNA Interference | 1 | 2015 | 266 | 0.480 |
Why?
|
| Endoscopic Ultrasound-Guided Fine Needle Aspiration | 1 | 2014 | 16 | 0.480 |
Why?
|
| Mediastinum | 1 | 2014 | 39 | 0.480 |
Why?
|
| Toll-Like Receptor 4 | 1 | 2015 | 114 | 0.470 |
Why?
|
| Internship and Residency | 2 | 2018 | 596 | 0.470 |
Why?
|
| Esophageal Fistula | 1 | 2014 | 7 | 0.470 |
Why?
|
| Neuroendocrine Cells | 1 | 2014 | 8 | 0.470 |
Why?
|
| Biphenyl Compounds | 1 | 2014 | 184 | 0.460 |
Why?
|
| Carcinoid Tumor | 1 | 2014 | 20 | 0.460 |
Why?
|
| Carcinoma, Neuroendocrine | 1 | 2014 | 13 | 0.460 |
Why?
|
| Fistula | 1 | 2014 | 29 | 0.460 |
Why?
|
| Tracheal Neoplasms | 2 | 2010 | 3 | 0.460 |
Why?
|
| Ultrasonography, Interventional | 1 | 2014 | 119 | 0.450 |
Why?
|
| Incidental Findings | 1 | 2014 | 42 | 0.450 |
Why?
|
| RNA, Small Interfering | 1 | 2015 | 434 | 0.450 |
Why?
|
| Neoplasm Invasiveness | 5 | 2020 | 369 | 0.450 |
Why?
|
| Genetic Therapy | 1 | 2015 | 291 | 0.440 |
Why?
|
| ErbB Receptors | 2 | 2014 | 239 | 0.440 |
Why?
|
| Pericardium | 1 | 2014 | 97 | 0.440 |
Why?
|
| Gene Expression Regulation, Neoplastic | 3 | 2012 | 756 | 0.440 |
Why?
|
| Up-Regulation | 1 | 2015 | 682 | 0.430 |
Why?
|
| Biopsy, Fine-Needle | 1 | 2012 | 76 | 0.420 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 3 | 2020 | 468 | 0.420 |
Why?
|
| Hypertension, Pulmonary | 1 | 2015 | 232 | 0.420 |
Why?
|
| Thoracotomy | 2 | 2017 | 25 | 0.400 |
Why?
|
| DNA-Binding Proteins | 1 | 2015 | 700 | 0.380 |
Why?
|
| Heart Diseases | 1 | 2014 | 276 | 0.380 |
Why?
|
| Transcription Factors | 1 | 2015 | 753 | 0.380 |
Why?
|
| Hernia, Hiatal | 1 | 2011 | 18 | 0.380 |
Why?
|
| Fundoplication | 1 | 2011 | 27 | 0.380 |
Why?
|
| Treatment Outcome | 13 | 2021 | 7029 | 0.380 |
Why?
|
| Laparoscopy | 2 | 2011 | 237 | 0.380 |
Why?
|
| Carcinoma | 3 | 2016 | 215 | 0.370 |
Why?
|
| Esophageal Diseases | 1 | 2011 | 95 | 0.370 |
Why?
|
| Cell Transdifferentiation | 1 | 2010 | 12 | 0.370 |
Why?
|
| Lung Abscess | 1 | 2010 | 4 | 0.370 |
Why?
|
| Sternoclavicular Joint | 1 | 2010 | 3 | 0.370 |
Why?
|
| Neoplastic Cells, Circulating | 1 | 2010 | 28 | 0.360 |
Why?
|
| Carcinoma, Adenoid Cystic | 1 | 2010 | 12 | 0.360 |
Why?
|
| Carcinoma, Mucoepidermoid | 1 | 2010 | 14 | 0.360 |
Why?
|
| Soft Tissue Infections | 1 | 2010 | 19 | 0.360 |
Why?
|
| Thorax | 2 | 2020 | 49 | 0.350 |
Why?
|
| Streptococcal Infections | 1 | 2010 | 53 | 0.350 |
Why?
|
| Esophagus | 2 | 2011 | 303 | 0.350 |
Why?
|
| Neoplasms | 2 | 2018 | 1667 | 0.340 |
Why?
|
| Female | 27 | 2019 | 38074 | 0.340 |
Why?
|
| Mesoderm | 1 | 2010 | 231 | 0.340 |
Why?
|
| Prognosis | 7 | 2018 | 2093 | 0.340 |
Why?
|
| NF-kappa B | 8 | 2005 | 432 | 0.330 |
Why?
|
| Mediastinitis | 1 | 2009 | 4 | 0.330 |
Why?
|
| RNA, Messenger | 2 | 2012 | 1664 | 0.330 |
Why?
|
| Aorta, Thoracic | 1 | 2010 | 211 | 0.320 |
Why?
|
| Boronic Acids | 3 | 2004 | 40 | 0.310 |
Why?
|
| Pyrazines | 3 | 2004 | 46 | 0.310 |
Why?
|
| Pulmonary Emphysema | 1 | 2009 | 71 | 0.310 |
Why?
|
| Animals | 10 | 2020 | 20881 | 0.310 |
Why?
|
| Arterial Occlusive Diseases | 1 | 2009 | 134 | 0.300 |
Why?
|
| Epithelial Cells | 1 | 2010 | 431 | 0.300 |
Why?
|
| Deoxycytidine | 2 | 2005 | 83 | 0.300 |
Why?
|
| Middle Aged | 21 | 2021 | 21147 | 0.300 |
Why?
|
| Histone Deacetylases | 2 | 2005 | 99 | 0.300 |
Why?
|
| Hamartoma | 1 | 2007 | 24 | 0.290 |
Why?
|
| Combined Modality Therapy | 4 | 2017 | 951 | 0.290 |
Why?
|
| Ablation Techniques | 2 | 2017 | 33 | 0.280 |
Why?
|
| Anti-Inflammatory Agents | 2 | 2020 | 234 | 0.270 |
Why?
|
| Skin Diseases | 1 | 2007 | 122 | 0.260 |
Why?
|
| HIV Infections | 1 | 2014 | 791 | 0.260 |
Why?
|
| Chemotherapy, Adjuvant | 3 | 2020 | 129 | 0.260 |
Why?
|
| Follow-Up Studies | 6 | 2018 | 3259 | 0.260 |
Why?
|
| Proteasome Inhibitors | 2 | 2004 | 29 | 0.250 |
Why?
|
| Aged | 17 | 2019 | 14862 | 0.240 |
Why?
|
| Risk Assessment | 8 | 2019 | 2007 | 0.240 |
Why?
|
| Phosphatidylinositol 3-Kinases | 1 | 2005 | 223 | 0.240 |
Why?
|
| Enzyme Inhibitors | 5 | 2005 | 659 | 0.240 |
Why?
|
| Muscle, Skeletal | 1 | 2007 | 396 | 0.230 |
Why?
|
| Adult | 18 | 2017 | 21403 | 0.230 |
Why?
|
| Neoplasm Proteins | 2 | 2014 | 307 | 0.230 |
Why?
|
| Lymph Node Excision | 2 | 2017 | 91 | 0.230 |
Why?
|
| Proto-Oncogene Proteins c-akt | 3 | 2020 | 331 | 0.220 |
Why?
|
| Survival Rate | 5 | 2013 | 1056 | 0.220 |
Why?
|
| Barrett Esophagus | 2 | 2012 | 57 | 0.200 |
Why?
|
| Cryopreservation | 2 | 2014 | 103 | 0.200 |
Why?
|
| Tumor Cells, Cultured | 4 | 2008 | 852 | 0.190 |
Why?
|
| Transcription, Genetic | 6 | 2005 | 562 | 0.190 |
Why?
|
| Snakes | 1 | 2020 | 2 | 0.190 |
Why?
|
| Histone Deacetylase Inhibitors | 5 | 2006 | 116 | 0.190 |
Why?
|
| Phosphorylation | 4 | 2020 | 1200 | 0.180 |
Why?
|
| Glycogen Synthase Kinase 3 beta | 1 | 2020 | 57 | 0.180 |
Why?
|
| A549 Cells | 1 | 2020 | 50 | 0.180 |
Why?
|
| Ketorolac | 1 | 2020 | 11 | 0.180 |
Why?
|
| Proteolysis | 1 | 2020 | 97 | 0.170 |
Why?
|
| Mastectomy, Segmental | 1 | 2019 | 64 | 0.170 |
Why?
|
| Respiratory Physiological Phenomena | 1 | 2019 | 10 | 0.170 |
Why?
|
| Small Cell Lung Carcinoma | 1 | 2019 | 17 | 0.170 |
Why?
|
| Tomography, X-Ray Computed | 7 | 2019 | 2324 | 0.170 |
Why?
|
| PTEN Phosphohydrolase | 1 | 2020 | 108 | 0.170 |
Why?
|
| Smoking | 2 | 2021 | 1452 | 0.170 |
Why?
|
| Bronchial Neoplasms | 1 | 2019 | 12 | 0.160 |
Why?
|
| Positron-Emission Tomography | 3 | 2010 | 160 | 0.160 |
Why?
|
| Plasmacytoma | 1 | 2019 | 15 | 0.160 |
Why?
|
| Bronchi | 1 | 2019 | 59 | 0.160 |
Why?
|
| Hydroxamic Acids | 4 | 2006 | 84 | 0.160 |
Why?
|
| Enzyme Activation | 1 | 2020 | 791 | 0.160 |
Why?
|
| Transcription Factor RelA | 4 | 2006 | 47 | 0.160 |
Why?
|
| Fibrin Tissue Adhesive | 1 | 2018 | 17 | 0.160 |
Why?
|
| Surgical Wound Dehiscence | 1 | 2018 | 20 | 0.160 |
Why?
|
| Mentors | 1 | 2018 | 81 | 0.150 |
Why?
|
| Extracorporeal Circulation | 1 | 2018 | 26 | 0.150 |
Why?
|
| Esophageal Perforation | 1 | 2017 | 13 | 0.150 |
Why?
|
| Cell Movement | 1 | 2020 | 630 | 0.150 |
Why?
|
| Disease-Free Survival | 4 | 2012 | 349 | 0.150 |
Why?
|
| Interleukin-2 | 1 | 2018 | 133 | 0.150 |
Why?
|
| Lymphatic Metastasis | 3 | 2017 | 274 | 0.150 |
Why?
|
| Cell Proliferation | 2 | 2020 | 1174 | 0.150 |
Why?
|
| Empyema, Pleural | 1 | 2017 | 13 | 0.140 |
Why?
|
| Bronchopulmonary Sequestration | 1 | 2016 | 7 | 0.140 |
Why?
|
| Dipeptidyl Peptidase 4 | 1 | 2016 | 15 | 0.140 |
Why?
|
| Swine | 1 | 2018 | 672 | 0.140 |
Why?
|
| Postoperative Complications | 2 | 2020 | 1615 | 0.140 |
Why?
|
| Retrospective Studies | 7 | 2019 | 7277 | 0.140 |
Why?
|
| Lysophospholipids | 1 | 2018 | 209 | 0.140 |
Why?
|
| Aortic Aneurysm | 1 | 2016 | 77 | 0.140 |
Why?
|
| Sequence Analysis, RNA | 1 | 2016 | 34 | 0.140 |
Why?
|
| Recurrence | 2 | 2021 | 948 | 0.130 |
Why?
|
| Bortezomib | 3 | 2004 | 45 | 0.130 |
Why?
|
| Immunotherapy | 1 | 2018 | 215 | 0.130 |
Why?
|
| Sphingosine | 1 | 2018 | 315 | 0.130 |
Why?
|
| Anti-Bacterial Agents | 3 | 2017 | 1026 | 0.130 |
Why?
|
| Models, Genetic | 1 | 2016 | 161 | 0.130 |
Why?
|
| Cell Survival | 6 | 2014 | 901 | 0.130 |
Why?
|
| Signal Transduction | 2 | 2004 | 2689 | 0.130 |
Why?
|
| Pulmonary Disease, Chronic Obstructive | 1 | 2018 | 207 | 0.130 |
Why?
|
| Biopsy | 3 | 2019 | 540 | 0.130 |
Why?
|
| Biopsy, Needle | 2 | 2014 | 191 | 0.120 |
Why?
|
| Topoisomerase I Inhibitors | 1 | 2014 | 8 | 0.120 |
Why?
|
| Antimetabolites, Antineoplastic | 2 | 2005 | 77 | 0.120 |
Why?
|
| Camptothecin | 1 | 2014 | 39 | 0.120 |
Why?
|
| MAP Kinase Kinase Kinases | 1 | 2014 | 34 | 0.120 |
Why?
|
| Severity of Illness Index | 2 | 2011 | 1851 | 0.120 |
Why?
|
| Embolization, Therapeutic | 1 | 2016 | 150 | 0.120 |
Why?
|
| Mice, Nude | 2 | 2005 | 294 | 0.120 |
Why?
|
| Truth Disclosure | 1 | 2014 | 48 | 0.120 |
Why?
|
| Hyperplasia | 1 | 2014 | 89 | 0.110 |
Why?
|
| Thoracic Wall | 1 | 2014 | 20 | 0.110 |
Why?
|
| Carcinoma, Signet Ring Cell | 1 | 2013 | 2 | 0.110 |
Why?
|
| Medical Errors | 1 | 2014 | 80 | 0.110 |
Why?
|
| Flail Chest | 1 | 2013 | 13 | 0.110 |
Why?
|
| Benzimidazoles | 1 | 2014 | 128 | 0.110 |
Why?
|
| Immunohistochemistry | 2 | 2014 | 1174 | 0.110 |
Why?
|
| Software | 1 | 2016 | 418 | 0.110 |
Why?
|
| Rib Fractures | 1 | 2013 | 37 | 0.110 |
Why?
|
| Cell Line, Tumor | 6 | 2014 | 1851 | 0.110 |
Why?
|
| Fracture Fixation, Internal | 1 | 2013 | 68 | 0.110 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2016 | 627 | 0.110 |
Why?
|
| Cell Cycle | 2 | 2004 | 312 | 0.110 |
Why?
|
| Necrosis | 2 | 2011 | 239 | 0.100 |
Why?
|
| Respiration, Artificial | 1 | 2013 | 190 | 0.100 |
Why?
|
| Chemoradiotherapy, Adjuvant | 1 | 2012 | 33 | 0.100 |
Why?
|
| Esophagoscopy | 1 | 2012 | 72 | 0.100 |
Why?
|
| Wounds, Nonpenetrating | 1 | 2013 | 131 | 0.100 |
Why?
|
| Time Factors | 4 | 2019 | 4655 | 0.100 |
Why?
|
| Intersectoral Collaboration | 3 | 2016 | 27 | 0.100 |
Why?
|
| Genetic Markers | 1 | 2012 | 144 | 0.100 |
Why?
|
| Chemoradiotherapy | 1 | 2012 | 54 | 0.100 |
Why?
|
| Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization | 1 | 2014 | 306 | 0.100 |
Why?
|
| Molecular Targeted Therapy | 1 | 2012 | 170 | 0.100 |
Why?
|
| Sphingolipids | 1 | 2014 | 337 | 0.100 |
Why?
|
| Biomarkers, Tumor | 2 | 2016 | 508 | 0.100 |
Why?
|
| Mucous Membrane | 1 | 2011 | 66 | 0.090 |
Why?
|
| Cell Transformation, Neoplastic | 1 | 2012 | 235 | 0.090 |
Why?
|
| Mutation | 2 | 2014 | 1213 | 0.090 |
Why?
|
| Pectoralis Muscles | 1 | 2010 | 12 | 0.090 |
Why?
|
| Tracheoesophageal Fistula | 1 | 2010 | 15 | 0.090 |
Why?
|
| Endoscopy, Digestive System | 1 | 2011 | 78 | 0.090 |
Why?
|
| Syndrome | 1 | 2011 | 255 | 0.090 |
Why?
|
| Ceramides | 1 | 2014 | 578 | 0.090 |
Why?
|
| Lymphoma, Large-Cell, Anaplastic | 1 | 2010 | 3 | 0.090 |
Why?
|
| Fibrosis | 2 | 2009 | 371 | 0.090 |
Why?
|
| Palliative Care | 1 | 2012 | 271 | 0.090 |
Why?
|
| Proton Pump Inhibitors | 1 | 2011 | 91 | 0.090 |
Why?
|
| Aged, 80 and over | 4 | 2014 | 4848 | 0.090 |
Why?
|
| Transplantation, Homologous | 1 | 2010 | 242 | 0.090 |
Why?
|
| Histoplasma | 1 | 2009 | 4 | 0.090 |
Why?
|
| Histoplasmosis | 1 | 2009 | 5 | 0.090 |
Why?
|
| Mediastinal Diseases | 1 | 2009 | 15 | 0.090 |
Why?
|
| Chylothorax | 1 | 2009 | 11 | 0.090 |
Why?
|
| Granuloma | 1 | 2009 | 21 | 0.090 |
Why?
|
| Pericardial Effusion | 1 | 2009 | 15 | 0.090 |
Why?
|
| Surgical Flaps | 1 | 2010 | 120 | 0.080 |
Why?
|
| Transcriptional Activation | 3 | 2006 | 226 | 0.080 |
Why?
|
| Colorectal Neoplasms | 1 | 2014 | 561 | 0.080 |
Why?
|
| Acute Disease | 1 | 2011 | 658 | 0.080 |
Why?
|
| Donor Selection | 1 | 2009 | 29 | 0.080 |
Why?
|
| Pleural Effusion | 1 | 2009 | 74 | 0.080 |
Why?
|
| Lymphatic Diseases | 1 | 2009 | 27 | 0.080 |
Why?
|
| Wound Healing | 1 | 2011 | 260 | 0.080 |
Why?
|
| Gamma Rays | 1 | 2008 | 64 | 0.080 |
Why?
|
| Risk Factors | 3 | 2019 | 5731 | 0.080 |
Why?
|
| Cancer Vaccines | 1 | 2008 | 61 | 0.080 |
Why?
|
| Ultraviolet Rays | 1 | 2008 | 130 | 0.080 |
Why?
|
| Angiography | 1 | 2009 | 194 | 0.080 |
Why?
|
| Gene Expression Profiling | 2 | 2014 | 498 | 0.080 |
Why?
|
| Subcutaneous Fat | 1 | 2007 | 5 | 0.070 |
Why?
|
| Protease Inhibitors | 2 | 2006 | 76 | 0.070 |
Why?
|
| Intubation, Intratracheal | 1 | 2008 | 99 | 0.070 |
Why?
|
| Angiogenesis Inhibitors | 2 | 2006 | 64 | 0.070 |
Why?
|
| Phenotype | 1 | 2010 | 947 | 0.070 |
Why?
|
| Interleukin-8 | 2 | 2004 | 71 | 0.070 |
Why?
|
| Proto-Oncogene Proteins | 2 | 2014 | 411 | 0.070 |
Why?
|
| Employee Performance Appraisal | 1 | 2007 | 12 | 0.070 |
Why?
|
| Biomarkers | 1 | 2012 | 1593 | 0.070 |
Why?
|
| p300-CBP Transcription Factors | 1 | 2006 | 3 | 0.070 |
Why?
|
| Models, Organizational | 1 | 2007 | 97 | 0.070 |
Why?
|
| Mice | 3 | 2014 | 8474 | 0.070 |
Why?
|
| Alcohol Drinking | 1 | 2012 | 805 | 0.070 |
Why?
|
| Task Performance and Analysis | 1 | 2007 | 150 | 0.070 |
Why?
|
| General Surgery | 1 | 2007 | 95 | 0.070 |
Why?
|
| United States | 3 | 2019 | 7367 | 0.070 |
Why?
|
| Emergency Medicine | 1 | 2007 | 88 | 0.070 |
Why?
|
| Chromones | 1 | 2005 | 33 | 0.070 |
Why?
|
| Stents | 1 | 2010 | 657 | 0.070 |
Why?
|
| Morpholines | 1 | 2005 | 79 | 0.060 |
Why?
|
| Stomach | 1 | 2005 | 80 | 0.060 |
Why?
|
| Patient Selection | 1 | 2009 | 592 | 0.060 |
Why?
|
| Melanoma | 1 | 2008 | 335 | 0.060 |
Why?
|
| Tumor Stem Cell Assay | 1 | 2004 | 30 | 0.060 |
Why?
|
| Survival Analysis | 3 | 2014 | 714 | 0.060 |
Why?
|
| Wounds and Injuries | 1 | 2008 | 334 | 0.060 |
Why?
|
| Gastric Bypass | 1 | 2005 | 83 | 0.060 |
Why?
|
| Drug Screening Assays, Antitumor | 1 | 2004 | 111 | 0.060 |
Why?
|
| Butyrates | 1 | 2004 | 14 | 0.060 |
Why?
|
| Critical Care | 1 | 2007 | 263 | 0.060 |
Why?
|
| Multienzyme Complexes | 1 | 2004 | 50 | 0.060 |
Why?
|
| Cysteine Endopeptidases | 1 | 2004 | 39 | 0.060 |
Why?
|
| Proteasome Endopeptidase Complex | 1 | 2004 | 69 | 0.060 |
Why?
|
| Xenograft Model Antitumor Assays | 1 | 2004 | 304 | 0.060 |
Why?
|
| Young Adult | 2 | 2011 | 5717 | 0.050 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2004 | 710 | 0.050 |
Why?
|
| Reactive Oxygen Species | 1 | 2004 | 499 | 0.050 |
Why?
|
| Drainage | 2 | 2017 | 133 | 0.050 |
Why?
|
| Age Factors | 3 | 2013 | 1864 | 0.050 |
Why?
|
| Adolescent | 2 | 2011 | 8912 | 0.050 |
Why?
|
| Child | 1 | 2011 | 6405 | 0.040 |
Why?
|
| ras Proteins | 2 | 2014 | 102 | 0.040 |
Why?
|
| Clinical Trials as Topic | 1 | 2004 | 848 | 0.040 |
Why?
|
| Radiotherapy, Adjuvant | 1 | 2019 | 125 | 0.040 |
Why?
|
| Tissue Adhesives | 1 | 2018 | 17 | 0.040 |
Why?
|
| Thoracentesis | 1 | 2017 | 8 | 0.040 |
Why?
|
| Datasets as Topic | 1 | 2017 | 53 | 0.040 |
Why?
|
| Databases, Factual | 1 | 2019 | 622 | 0.030 |
Why?
|
| Esophagogastric Junction | 1 | 2016 | 118 | 0.030 |
Why?
|
| DNA, Intergenic | 1 | 2016 | 8 | 0.030 |
Why?
|
| RNA Editing | 1 | 2016 | 5 | 0.030 |
Why?
|
| Discriminant Analysis | 1 | 2016 | 36 | 0.030 |
Why?
|
| Introns | 1 | 2016 | 68 | 0.030 |
Why?
|
| Proportional Hazards Models | 2 | 2010 | 792 | 0.030 |
Why?
|
| 3' Untranslated Regions | 1 | 2016 | 56 | 0.030 |
Why?
|
| Exons | 1 | 2016 | 122 | 0.030 |
Why?
|
| Consensus | 1 | 2017 | 211 | 0.030 |
Why?
|
| Reoperation | 2 | 2009 | 467 | 0.030 |
Why?
|
| Neoplasm Recurrence, Local | 2 | 2010 | 446 | 0.030 |
Why?
|
| Diagnosis, Differential | 1 | 2019 | 1140 | 0.030 |
Why?
|
| Machine Learning | 1 | 2017 | 170 | 0.030 |
Why?
|
| Early Termination of Clinical Trials | 1 | 2014 | 11 | 0.030 |
Why?
|
| Tissue Banks | 1 | 2014 | 13 | 0.030 |
Why?
|
| Drug Synergism | 2 | 2005 | 260 | 0.030 |
Why?
|
| Proto-Oncogene Proteins p21(ras) | 1 | 2014 | 78 | 0.030 |
Why?
|
| Societies, Medical | 1 | 2017 | 403 | 0.030 |
Why?
|
| Tissue Culture Techniques | 1 | 2014 | 62 | 0.030 |
Why?
|
| Cryoprotective Agents | 1 | 2014 | 31 | 0.030 |
Why?
|
| Protein Stability | 1 | 2014 | 90 | 0.030 |
Why?
|
| RNA Stability | 1 | 2014 | 55 | 0.030 |
Why?
|
| Cohort Studies | 2 | 2014 | 2358 | 0.030 |
Why?
|
| Evidence-Based Medicine | 1 | 2017 | 438 | 0.030 |
Why?
|
| Chromatin | 2 | 2005 | 76 | 0.030 |
Why?
|
| Workflow | 1 | 2014 | 100 | 0.030 |
Why?
|
| Fibrinolytic Agents | 1 | 2017 | 377 | 0.030 |
Why?
|
| Injury Severity Score | 1 | 2013 | 204 | 0.030 |
Why?
|
| Trauma Centers | 1 | 2013 | 197 | 0.030 |
Why?
|
| Proteomics | 1 | 2014 | 246 | 0.030 |
Why?
|
| Intensive Care Units | 1 | 2013 | 344 | 0.020 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2014 | 1745 | 0.020 |
Why?
|
| Pilot Projects | 1 | 2014 | 1342 | 0.020 |
Why?
|
| Algorithms | 1 | 2016 | 1196 | 0.020 |
Why?
|
| Length of Stay | 1 | 2013 | 780 | 0.020 |
Why?
|
| Propensity Score | 1 | 2010 | 117 | 0.020 |
Why?
|
| Mediastinoscopy | 1 | 2009 | 13 | 0.020 |
Why?
|
| Chest Tubes | 1 | 2009 | 18 | 0.020 |
Why?
|
| Receptor Protein-Tyrosine Kinases | 1 | 2010 | 100 | 0.020 |
Why?
|
| Protein-Tyrosine Kinases | 1 | 2010 | 195 | 0.020 |
Why?
|
| Dose-Response Relationship, Radiation | 1 | 2008 | 84 | 0.020 |
Why?
|
| Chi-Square Distribution | 1 | 2010 | 546 | 0.020 |
Why?
|
| Adipose Tissue | 1 | 2009 | 221 | 0.020 |
Why?
|
| Calcinosis | 1 | 2009 | 241 | 0.020 |
Why?
|
| Retinoid X Receptors | 1 | 2006 | 26 | 0.020 |
Why?
|
| South Carolina | 1 | 2013 | 2752 | 0.020 |
Why?
|
| Cyclooxygenase 2 Inhibitors | 1 | 2006 | 46 | 0.020 |
Why?
|
| Life Tables | 1 | 2006 | 29 | 0.020 |
Why?
|
| Patient Simulation | 1 | 2007 | 64 | 0.020 |
Why?
|
| Blotting, Western | 1 | 2008 | 954 | 0.020 |
Why?
|
| Drug Evaluation | 1 | 2006 | 47 | 0.020 |
Why?
|
| Pleura | 1 | 2006 | 25 | 0.020 |
Why?
|
| Breast Neoplasms | 1 | 2016 | 1536 | 0.020 |
Why?
|
| Serine | 1 | 2006 | 99 | 0.020 |
Why?
|
| Genes, Reporter | 1 | 2006 | 191 | 0.020 |
Why?
|
| Logistic Models | 1 | 2010 | 1420 | 0.020 |
Why?
|
| Surgical Stapling | 1 | 2005 | 3 | 0.020 |
Why?
|
| Esophagostomy | 1 | 2005 | 3 | 0.020 |
Why?
|
| Jejunum | 1 | 2005 | 26 | 0.020 |
Why?
|
| Jejunostomy | 1 | 2005 | 26 | 0.020 |
Why?
|
| Anastomosis, Surgical | 1 | 2005 | 104 | 0.020 |
Why?
|
| Acetylation | 1 | 2005 | 94 | 0.020 |
Why?
|
| Neoplasm Metastasis | 1 | 2006 | 306 | 0.020 |
Why?
|
| Program Evaluation | 1 | 2007 | 502 | 0.020 |
Why?
|
| Active Transport, Cell Nucleus | 1 | 2004 | 55 | 0.010 |
Why?
|
| Sulfones | 1 | 2004 | 45 | 0.010 |
Why?
|
| Gastrostomy | 1 | 2005 | 110 | 0.010 |
Why?
|
| Nitriles | 1 | 2004 | 68 | 0.010 |
Why?
|
| Hospital Mortality | 1 | 2006 | 384 | 0.010 |
Why?
|
| Surgical Wound Infection | 1 | 2005 | 168 | 0.010 |
Why?
|
| Enteral Nutrition | 1 | 2005 | 157 | 0.010 |
Why?
|
| bcl-X Protein | 1 | 2003 | 36 | 0.010 |
Why?
|
| Anti-Infective Agents | 1 | 2004 | 166 | 0.010 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 1 | 2003 | 174 | 0.010 |
Why?
|
| Cell Line | 1 | 2006 | 1752 | 0.010 |
Why?
|
| Matrix Metalloproteinase 9 | 1 | 2003 | 160 | 0.010 |
Why?
|
| Trans-Activators | 1 | 2003 | 237 | 0.010 |
Why?
|
| Nuclear Proteins | 1 | 2003 | 271 | 0.010 |
Why?
|
| Mitochondria | 1 | 2004 | 643 | 0.010 |
Why?
|
| Sex Factors | 1 | 2003 | 1266 | 0.010 |
Why?
|
| Gene Expression Regulation | 1 | 2003 | 1293 | 0.010 |
Why?
|